Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...
Hosted on MSN22h
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...
Dallas Innovates5d
Alpha Cognition Inks $44M Licensing Agreement With China’s CMS for Alpha’s ZUNVEYL Alzheimer’s Drug
The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...
Business Wire7d
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild ...
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing ...
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and ...
Benzinga.com7d
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition licenses Zunveyl to China Medical System for $44M, covering Asia (excl. Japan), Australia, and New Zealand. ALPHA-1062 shows promise in reducing neuroinflammation and ...
Nasdaq7d
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and commercialization of Zunveyl in Asia, Australia and New Zealand.
AOL7d
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition remains on track to launch Zunveyl in the United States in Q1 2025. The company will provide a corporate update and present its Launch Strategy on January 28, 2025.